Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistanceKristina Lindemann, Anna DeFazio, Kathryn Alsop et al.|Gynecologic Oncology|2018Cited by 52
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey‐Sei Kok, Rachel O’Connell, Peter Grant et al.|Journal of Gynecologic Oncology|2019Cited by 26
Paragon (ANZGOG-0903)Anthony Bonaventura, Michael Friedländer, Rachel O’Connell et al.|International Journal of Gynecological Cancer|2017Cited by 22